Pacific Biosciences of California, Inc.
PACB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $154 | $201 | $128 | $131 |
| % Growth | -23.2% | 56.3% | -1.7% | – |
| Cost of Goods Sold | $117 | $148 | $79 | $72 |
| Gross Profit | $37 | $53 | $49 | $59 |
| % Margin | 24.2% | 26.3% | 38.2% | 45.1% |
| R&D Expenses | $135 | $187 | $193 | $113 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $175 | $170 | $161 | $124 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $202 | $30 | $2 | $32 |
| Operating Expenses | $512 | $387 | $356 | $269 |
| Operating Income | -$474 | -$334 | -$307 | -$210 |
| % Margin | -308% | -166.8% | -239.4% | -161.2% |
| Other Income/Exp. Net | $165 | $16 | -$7 | -$64 |
| Pre-Tax Income | -$310 | -$318 | -$314 | -$275 |
| Tax Expense | $0 | -$11 | $0 | -$94 |
| Net Income | -$310 | -$307 | -$314 | -$181 |
| % Margin | -201.2% | -153% | -244.9% | -138.9% |
| EPS | -1.13 | -1.21 | -1.4 | -0.89 |
| % Growth | 6.6% | 13.6% | -57.3% | – |
| EPS Diluted | -1.07 | -1.21 | -1.4 | -0.89 |
| Weighted Avg Shares Out | 274 | 254 | 225 | 204 |
| Weighted Avg Shares Out Dil | 288 | 254 | 225 | 204 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $13 | $14 | $15 | $13 |
| Depreciation & Amortization | $53 | $33 | $17 | $12 |
| EBITDA | -$243 | -$271 | -$282 | -$251 |
| % Margin | -157.6% | -135.2% | -220% | -192.1% |